Stock listing

Tradegate:YP1A Immutep Ltd Aktie

German listing (Tradegate) of Immutep Ltd · home listing ASX:IMM

Follow Immutep Ltd into a list and get an email when it puts out news.

Home listing price · ASX:IMM

$0.024 AUD +0.001 (+4.3%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, ASX:IMM

Past year -90.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.024 – $0.026 AUDNov 20, 2026
Volume
2.38M sharesNov 20, 2026
Market cap
$35.37M AUDAt the close on Nov 20, 2026 · price × 1.47B shares outstanding
52-week range
$0.021 – $0.470 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$350,460 AUDMedian day 6.21M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Immutep Ltd logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:IMM · Home$0.024 AUD+0.001 (+4.3%)2,376,037$0.025$0.026$0.024$0.023Close on Nov 20, 2026
NASDAQ:IMMP$3.11 USD-0.31 (-9.1%)44,784$3.41$3.41$3.093$3.42Close on Nov 20, 2026
OTC:PRRUF$0.02 USD0.00 (0.0%)—$0.02$0.02$0.02$0.02Close on Nov 6, 2026
Frankfurt:YP1B€0.014 EUR+0.002 (+16.7%)73,006€0.014€0.014€0.014€0.012Close on Nov 19, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:IMM · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.024+0.001+4.3%$0.025$0.026$0.0242,376,037
$0.023-0.001-4.2%$0.025$0.025$0.0238,909,874
$0.0240.0000.0%$0.025$0.025$0.0233,307,249
$0.024-0.001-4.0%$0.026$0.026$0.0243,381,854
$0.0250.0000.0%$0.025$0.026$0.0243,136,623
$0.0250.0000.0%$0.026$0.026$0.0244,261,941
$0.025+0.001+4.2%$0.023$0.027$0.0237,036,939
$0.024-0.002-7.7%$0.025$0.026$0.0249,241,523
$0.026+0.005+23.8%$0.026$0.027$0.02538,737,027
$0.0210.0000.0%$0.021$0.022$0.0216,509,569
$0.0210.0000.0%$0.022$0.022$0.0214,193,550
$0.0210.0000.0%$0.022$0.022$0.0214,357,045
$0.021-0.001-4.5%$0.022$0.022$0.0212,424,641
$0.022-0.001-4.3%$0.023$0.023$0.0211,724,657
$0.0230.0000.0%$0.023$0.024$0.02112,265,937
$0.023-0.001-4.2%$0.025$0.026$0.0233,434,257
$0.024+0.002+9.1%$0.022$0.025$0.0224,766,810
$0.022-0.001-4.3%$0.022$0.024$0.0227,379,385
$0.0230.0000.0%$0.022$0.023$0.022833,486
$0.023+0.001+4.5%$0.023$0.023$0.022554,119
$0.022-0.002-8.3%$0.024$0.025$0.0226,219,324
$0.024+0.001+4.3%$0.024$0.024$0.0232,086,815
$0.0230.0000.0%$0.024$0.024$0.0231,879,378
$0.0230.0000.0%$0.024$0.025$0.0235,763,289
$0.0230.0000.0%$0.024$0.025$0.0233,393,799
$0.023-0.002-8.0%$0.025$0.025$0.02211,987,136
$0.025-0.001-3.8%$0.025$0.026$0.0249,183,279
$0.026-0.001-3.7%$0.026$0.027$0.0255,288,830
$0.027+0.001+3.8%$0.027$0.028$0.02515,856,060
$0.026-0.002-7.1%$0.029$0.029$0.02612,156,580
$0.028-0.002-6.7%$0.029$0.029$0.0286,675,855
$0.030-0.001-3.2%$0.031$0.032$0.02912,583,749
$0.0310.0000.0%$0.031$0.032$0.0308,332,446
$0.031-0.001-3.1%$0.030$0.033$0.0307,067,452
$0.032-0.001-3.0%$0.034$0.034$0.03024,951,561
$0.033-0.001-2.9%$0.034$0.034$0.0324,232,785
$0.0340.0000.0%$0.033$0.035$0.0334,497,329
$0.0340.0000.0%$0.035$0.035$0.0337,182,179
$0.034-0.002-5.6%$0.036$0.037$0.03317,593,080
$0.036-0.002-5.3%$0.037$0.038$0.03515,925,520
$0.038-0.003-7.3%$0.040$0.040$0.03617,738,514
$0.0410.0000.0%$0.040$0.042$0.03916,350,285
$0.041+0.001+2.5%$0.041$0.042$0.0406,454,957
$0.040+0.002+5.3%$0.039$0.042$0.03917,812,396
$0.038-0.007-15.6%$0.045$0.045$0.03888,325,211
$0.045-0.002-4.3%$0.046$0.047$0.0449,021,036
$0.047+0.002+4.4%$0.045$0.048$0.0448,697,659
$0.045-0.002-4.3%$0.046$0.048$0.04418,435,318
$0.047-0.009-16.1%$0.054$0.054$0.04721,113,896
$0.056+0.012+27.3%$0.050$0.057$0.04445,816,066
$0.044-0.002-4.3%$0.045$0.045$0.04212,826,028
$0.046-0.001-2.1%$0.046$0.048$0.0458,083,492
$0.047+0.001+2.2%$0.047$0.049$0.0465,376,462
$0.046-0.002-4.2%$0.048$0.048$0.0454,456,966
$0.048+0.001+2.1%$0.048$0.048$0.0466,506,328
$0.047-0.002-4.1%$0.049$0.050$0.0473,338,224
$0.049-0.002-3.9%$0.051$0.051$0.0492,354,360
$0.051+0.003+6.2%$0.049$0.051$0.0474,914,512
$0.048-0.002-4.0%$0.049$0.050$0.0484,218,452
$0.0500.0000.0%$0.050$0.051$0.0492,519,726
$0.050-0.002-3.8%$0.052$0.052$0.0503,104,572
$0.052-0.002-3.7%$0.053$0.054$0.0511,697,268
$0.054+0.001+1.9%$0.053$0.054$0.0514,418,485
$0.0530.0000.0%$0.052$0.053$0.0523,450,655
$0.053-0.001-1.9%$0.053$0.055$0.0524,321,750
$0.054+0.003+5.9%$0.051$0.054$0.0516,202,833

Splits

4 splits since 2007 · ASX:IMM · every price before a split is adjusted for it

DayRatioWhat
1.0157-for-1Split
1-for-10Consolidation
21-for-17Split
18-for-17Split
Ticker
Tradegate:YP1A
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Tradegate
Currency
EUR

What changed lately

Latest news

All Immutep Ltd news

Immutep Ltd on 6ix

Sector
Health care
Industry
Biotechnology
News releases
63 in the last 12 months · 336 in all · newest Nov 18, 2026 · oldest 2016
Decks
112 decks · latest Aug 20, 2026

Where Immutep Ltd is listed

ListingExchangeCountryCurrency
ASX:IMM · Home listingASXAustraliaAUD
NASDAQ:IMMPNASDAQUnited StatesUSD
gettex:YP1BgettexGermanyEUR
LS Exchange:A2H81HLS ExchangeGermanyEUR
LS Exchange:A2H8YLLS ExchangeGermanyEUR
OTC:PRRUFOTCUnited StatesUSD
BOATS:IMMPBOATSUnited StatesUSD
Lang & Schwarz:A2H81HLang & SchwarzGermanyEUR
gettex:YP1AgettexGermanyEUR
Frankfurt:YP1BFrankfurtGermanyEUR
Lang & Schwarz:A2H8YLLang & SchwarzGermanyEUR
Stuttgart:YP1AStuttgartGermanyEUR
Dusseldorf:YP1BDusseldorfGermanyEUR
Hamburg:YP1BHamburgGermanyEUR
Stuttgart:YP1BStuttgartGermanyEUR
Dusseldorf:YP1ADusseldorfGermanyEUR
Frankfurt:YP1AFrankfurtGermanyEUR
Hamburg:YP1AHamburgGermanyEUR
Munich:YP1AMunichGermanyEUR
Munich:YP1BMunichGermanyEUR
Tradegate:YP1A · This pageTradegateGermanyEUR
Tradegate:YP1BTradegateGermanyEUR

Valuation

EV/sales −2.6× against a median of 3.8×: the lowest of 4 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
−$37.66M AUD
P/E
Loss
EV/sales
−2.6×
EV/EBITDA
Negative EBITDA
Price/book
0.6×
Gross margin
83.0%
Operating margin
−576.2%
Net margin
−544.8%
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Immutep Ltd · ASX:IMMUS$23.41M−US$24.93Mn/a−2.6×n/a0.6×−544.8%0.0×n/a
Original Biomedicals Co Ltd · TPEX:6483US$23.81MUS$21.67Mn/a1,875×n/a7.1×n/a0.0×n/a
Sernova Biotherapeutics Inc · TSX:SVAUS$23.70MUS$25.46Mn/an/an/an/an/an/a0.40
Scynexis, Inc. · NASDAQ:SCYXUS$23.69M−US$21.66Mn/a−1.1×n/a0.4×−53.5%0.0×1.76
ImmuPharma plc · LSE:IMMUS$23.68MUS$22.77Mn/an/an/a9.9×n/a0.0×n/a
Organoidsciences Ltd. · KRX:476040US$23.46MUS$6.52Mn/a3.8×n/a1.1×−814.8%0.4×n/a
ABVC BioPharma, Inc. · NASDAQ:ABVCUS$23.37MUS$25.81Mn/an/an/a1.8×n/a0.2×1.39
Incannex Healthcare Inc. · NASDAQ:IXHLUS$23.33M−US$44.85Mn/an/an/a0.3×n/a0.0×0.98
Actinogen Medical Limited · ASX:ACWUS$23.08MUS$15.17Mn/an/an/a1.6×n/a0.2×n/a
BioNxt Solutions Inc · CSE:BNXTUS$22.78MUS$22.72Mn/an/an/an/an/an/a0.22
Polyrizon Ltd. · NASDAQ:PLRZUS$22.61MUS$7.56Mn/an/an/a0.9×n/a0.0×0.67
Median of the othersUS$23.42MUS$18.42M3.8×1.4×−434.1%0.0×0.83

Forecasts

Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
0.11 AUD · Analysts' mean
EPS, year to Jun 2027
-0.017 · 3 analysts
Revenue, year to Jun 2027
4M · 1 analyst

Team and board

Officers

OfficerRole
Marc VoigtChief Executive Officer & Executive Director
Deanne MillerChief Operating Officer, General Counsel & Company Secretary
James FlinnIntellectual Property Director & Legal Counsel
David FangFinance Director & Assistant Company Secretary
Chris BastaVP, Investor Relations and Corporate Communications
Christian MuellerChief Development Officer
Frédéric TriebelChief Scientific Officer & Executive Director
Stephan WinckelsChief Medical Officer

Board

DirectorRole
Russell HowardNon-Executive Chairman
Deanne MillerChief Operating Officer, General Counsel & Company Secretary
Frédéric TriebelChief Scientific Officer & Executive Director
Lis BoyceNon-Executive Director
Marc VoigtChief Executive Officer & Executive Director

Events

QuarterResultsShare move
Quarter to Sep 30, 2025Dec 3, 2025−8.9%
Q4 2025Aug 28, 2025−4.1%
Q3 2025May 28, 20250.0%
Q2 2025Feb 26, 2025−1.6%
Q1 2025Nov 27, 2024+3.2%
Q4 2024Aug 29, 2024+6.6%
Q3 2024May 29, 20240.0%
Q2 2024Feb 27, 2024+9.2%
Q1 2024Oct 31, 2023 · Before open−1.6%
Q4 2023Aug 30, 2023 · Before open+1.8%
All 20 quarters
QuarterResultsShare move
Q3 2023Apr 27, 2023 · Before open0.0%
Q2 2023Feb 24, 2023 · After close−2.0%
Q1 2023Nov 30, 2022−1.4%
Q4 2022Aug 31, 2022 · After close−3.5%
Q3 2022Jun 1, 20220.0%
Q2 2022Feb 23, 2022 · Before open+6.0%
Q1 2022Dec 1, 2021−1.1%
Q4 2021Aug 30, 2021+1.9%
Quarter to Mar 31, 2021Jun 2, 20210.0%
Quarter to Dec 31, 2020Feb 23, 2021−10.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck30 slidesAug 20, 2026
Investor Presentation (February 2026)Investor deck39 slidesFeb 20, 2026
Shareholder Meeting (November 2025)Shareholder meeting24 slidesNov 27, 2025
Investor Presentation (October 2025)Investor deck37 slidesOctober 2025
Jefferies Global Healthcare Conference 2025Conference40 slidesJun 2, 2025
Investor Presentation (February 2025)Investor deck39 slidesFeb 5, 2025
Shareholder Meeting (November 2024)Shareholder meeting16 slidesNov 22, 2024
European Society for Medical Oncology (ESMO) Congress 2024Conference15 slidesSep 15, 2024
Investor Presentation (September 2024)Investor deck63 slidesSeptember 2024
Investor Presentation (August 2024)Investor deck60 slidesAug 21, 2024
Show 50 decks
DeckKindSlidesDate
Investor Presentation (August 2024)Investor deck61 slidesAugust 2024
Technical Presentation (July 2024)Technical14 slidesJul 12, 2024
Technical Presentation (July 2024)Technical15 slidesJul 11, 2024
Corporate Update (June 2024)Corporate update24 slidesJun 26, 2024
Investor Presentation (June 2024)Investor deck66 slidesJun 3, 2024
Investor Presentation (March 2024)Investor deck50 slidesMarch 2024
Investor Presentation (January 2024)Investor deck50 slidesJan 8, 2024
Shareholder Meeting (October 2023)Shareholder meeting34 slidesOct 24, 2023
ESMO Congress 2023Conference25 slidesOct 22, 2023
ESMO 2023Conference8 slidesOct 21, 2023
Investor Presentation (September 2023)Investor deck35 slidesSeptember 2023
Investor Presentation (June 2023)Investor deck39 slidesJune 2023
Investor Presentation (May 2023)Investor deck63 slidesMay 31, 2023
Investor Presentation (March 2023)Investor deck27 slidesMarch 2023
Investor Presentation (December 2022)Investor deck33 slidesDecember 2022
Shareholder Meeting (November 2022)Shareholder meeting22 slidesNov 23, 2022
Corporate Update (November 2022)Corporate update25 slidesNov 10, 2022
Investor Presentation (November 2022)Investor deck30 slidesNov 2, 2022
Non-Small Cell Cancer Drug Development Summit 2022Conference27 slidesSep 22, 2022
Conference Presentation (September 2022)Conference27 slidesSeptember 2022
ASCO 2022Conference27 slidesJun 6, 2022
Investor Presentation (May 2022)Investor deck35 slidesMay 24, 2022
Cowen 42nd Annual Health Care Conference (March 2022)Conference34 slidesMarch 2022
Shareholder Meeting (November 2021)Shareholder meeting22 slidesNov 26, 2021
Corporate Update (November 2021)Corporate update32 slidesNov 17, 2021
Investor Presentation (September 2021)Investor deck46 slidesSep 27, 2021
Shareholder Meeting (July 2021)Shareholder meeting24 slidesJul 26, 2021
Non-Small Cell Cancer Drug Development Summit (July 2021)Conference23 slidesJul 15, 2021
Investor Presentation (June 2021)Investor deck61 slidesJun 21, 2021
Corporate Update (June 2021)Corporate update38 slidesJun 10, 2021
Jefferies Virtual Healthcare Conference 2021Conference33 slidesJun 4, 2021
Investor Presentation (May 2021)Investor deck48 slidesMay 13, 2021
Investor Presentation (February 2021)Investor deck45 slidesFeb 2, 2021
Technical Presentation (December 2020)Technical25 slidesDec 11, 2020
Investor Presentation (November 2020)Investor deck52 slidesNov 19, 2020
World Immunotherapy Congress 2020Conference14 slidesNov 5, 2020
Shareholder Meeting (October 2020)Shareholder meeting21 slidesOct 27, 2020
BIO Asia July 2020Conference17 slidesJuly 2020
Investor Presentation (April 2020)Investor deck51 slidesApr 30, 2020
Investor Presentation (April 2020)Investor deck51 slidesApr 29, 2020

This page holds 50 of 112 decks. Open Decks

Open Decks

Financials

Annual, in AUD

Income statement

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue14.6M10.3M7.84M5.20M6.76M3.97M16.5M7.49M7.35M4.22M
Cost of revenue2.47M61.4M41.5M2.06M2.06M2.07M22.5M16.6M9.99M1.70M
Gross profit12.1M-56.4M-37.7M1.44M-1.89M1.79M-15.0M-16.5M-7.36M2.42M
Research and development76.7M49.8M31.5M28.8M25.3M12.0M15.6M13.8M9.99M7.53M
Selling, general and administrative9.58M8.64M8.85M8.68M7.21M6.28M6.34M6.13M7.24M4.35M
Operating income-83.9M-126.4M-88.1M-44.9M-38.4M-23.5M-16.0M-20.4M-11.7M-9.35M
Depreciation and amortization2.47M2.39M2.26M2.06M2.06M2.07M2.08M1.88M1.81M1.70M
EBITDA-81.4M-124.0M-85.8M-42.9M-36.3M-21.4M-13.9M-18.5M-9.88M-7.65M
Interest expense67.9K37.1K30.6K20.4K92.4K9.82K10.5K000
Income before tax-79.3M-61.4M-42.7M-39.9M-32.2M-29.9M-13.5M-18.3M-12.7M-10.1M
Income tax00034333701.68K-737.4K
Net income-79.3M-61.4M-42.7M-39.9M-32.2M-29.9M-13.5M-18.3M-12.7M-9.37M
Earnings per share, basic-0.05-0.04-0.04-0.04-0.04-0.05-0.03-5.29-4.63-0.40
Earnings per share, diluted-0.04-0.04-0.04-0.04-0.05-0.03-5.29-4.63-0.40

Balance sheet

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents68.9M67.4M161.8M123.4M80.0M60.6M26.3M16.6M23.5M12.2M
Short-term investments5.20M62.3M20.1M0
Receivables9.62M9.87M7.35M7.95M8.37M6.12M3.29M5.19M3.43M2.19M
Inventory2-1.11M465.0K111642.0K
Current assets80.6M149.1M191.4M135.0M90.8M68.4M31.2M23.5M28.6M15.9M
Property, plant and equipment63.5K63.1K83.1K37.9K40.9K49.4K53.0K26.4K24.2K
Goodwill110.0K110.0K110.0K110.0K110.0K110.0K110.0K110.0K110.0K110.0K
Total assets83.3M157.0M201.6M147.4M102.2M82.0M46.6M40.5M47.0M35.0M
Accounts payable5.89M10.6M9.56M9.02M5.75M4.78M2.93M5.06M3.66M2.59M
Current liabilities14.2M12.8M10.5M9.77M6.41M5.34M3.36M5.30M3.85M2.63M
Long-term debt0960.8K835.5K2.11M2.53M8.79M7.64M6.65M5.78M
Total debt1.05M1.63M1.59M1.44M1.84M2.90M9.05M7.64M13.3M11.6M
Total liabilities21.7M13.3M12.1M11.0M8.09M8.76M13.3M16.2M13.5M8.43M
Shareholders' equity61.5M143.6M189.5M136.5M94.1M73.3M33.3M24.4M33.5M26.5M
Shares outstanding1.47B1.46B1.20B880.2M849.0M604.3M426.9M346.8M266.8M211.9M

Cash flow

LineFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-55.5M-62.0M-34.8M-35.4M-30.2M-17.6M-10.8M-15.3M-7.78M-8.51M
Capital spending-92.9K-45.8K-29.2K-82.7K-22.9K-15.6K-19.3K-41.4K-11.9K-6.64K
Free cash flow-55.6M-62.1M-34.9M-35.4M-30.3M-17.7M-10.9M-15.3M-7.79M-8.51M
Cash from investing56.5M-38.5M-21.0M-82.7K-22.9K-15.6K-19.3K-41.4K-11.9K-6.64K
Cash from financing-214.4K-525.1K95.2M76.0M50.3M52.7M20.5M8.01M18.4M-8.53K
Dividends paid000
Share buybacks80.1M53.0M54.6M22.0M8.79M19.7M0
Change in cash1.46M-101.1M39.3M40.6M20.1M35.0M9.62M-7.32M10.6M-8.52M

Open Financials

Filings

FilingDateTypeFiled with
6-K · Report of a foreign issuerNov 19, 2026Current reportSEC
Encouraging Disease-Free Survival in Phase II Sarcoma TrialNov 18, 2026Operations updateASX
Immutep Investor UpdateNov 17, 2026Other filingsASX
Immutep Expands US Patents for Efti Combination TherapiesNov 10, 2026Other filingsASX
EFTISARC-NEO Survival Data reported in CTOS 2026 AbstractNov 10, 2026Operations updateASX
6-K · Report of a foreign issuerNov 10, 2026Current reportSEC
IMP761 Late-Breaking Abstract at ACR shows T-Cell InhibitionNov 8, 2026Operations updateASX
Upcoming Poster Presentations at CTOS and ESMO IO 2026Nov 4, 2026Other filingsASX
6-K · Report of a foreign issuerOct 30, 2026Current reportSEC
6-K · Report of a foreign issuerOct 29, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
Immutep Quarterly Activities Report and Appendix 4COct 28, 2026Quarterly reportASX
Immutep Receives A$2.16 million French R&D Tax IncentiveOct 27, 2026FinancingASX
Notice of Annual General Meeting/Proxy FormOct 26, 2026Meeting noticeASX
Appendix 4G and Corporate Governance StatementOct 26, 2026Other filingsASX
Annual Report to shareholdersOct 26, 2026Annual reportASX
Annual Report filed on Form 20-FOct 25, 2026Annual reportASX
20-F · Annual reportOct 23, 2026Annual reportSEC
Quality of Life Data from EFTISARC-NEO presented at ESMOOct 23, 2026Operations updateASX
Late-Breaking Abstract on IMP761 to be presented at ACR 2026Oct 18, 2026Other filingsASX
2026 Annual General Meeting and Key DatesOct 14, 2026Meeting noticeASX
6-K · Report of a foreign issuerOct 13, 2026Current reportSEC
Immutep & Monash Secure Further ARC Funding for LAG-3Oct 13, 2026Other filingsASX
Immutep Regains Compliance with NasdaqOct 12, 2026Compliance certificateASX
Audit and Risk Committee UpdateOct 9, 2026Other filingsASX
Final Director's Interest Notice - P MeyersOct 4, 2026List of directorsASX
Notification of cessation of securities - IMMOct 4, 2026FinancingASX
Resignation of Non-Executive DirectorOct 4, 2026Management or board changeASX
Change of Director's Interest Notice - P MeyersSep 30, 2026Ownership change noticeASX
Application for quotation of securities - IMMSep 30, 2026FinancingASX
Immutep receives Australian R&D Tax IncentiveSep 29, 2026FinancingASX
6-K · Report of a foreign issuerSep 22, 2026Current reportSEC
6-K · Report of a foreign issuerSep 11, 2026Current reportSEC
Immutep Outlines Focused Development Strategy for EftiSep 10, 2026Operations updateASX
S&P DJI Announces September 2026 Quarterly RebalanceSep 4, 2026Other filingsASX
6-K · Report of a foreign issuerSep 1, 2026Current reportSEC
Appendix 4E & 2026 Full Year Statutory AccountsAug 30, 2026Annual reportASX
Immutep Corporate PresentationAug 19, 2026Other filingsASX
6-K · Report of a foreign issuerJul 31, 2026Current reportSEC
Immutep Quarterly Activities Report and Appendix 4CJul 29, 2026Quarterly reportASX
6-K · Report of a foreign issuerJul 13, 2026Current reportSEC
6-K · Report of a foreign issuerJun 4, 2026Current reportSEC
UPLOAD · Letter from the SECMay 11, 2026Other filingsSEC
6-K · Report of a foreign issuerMay 1, 2026Current reportSEC
6-K · Report of a foreign issuerApr 30, 2026Current reportSEC
CORRESP · Letter to the SECApr 24, 2026Other filingsSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
6-K · Report of a foreign issuerApr 15, 2026Current reportSEC
Immutep receives FDA ODD for Efti in Soft Tissue SarcomaApr 14, 2026Operations updateASX
3 · Initial statement of ownershipApr 13, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 13, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 7, 2026Insider tradeSEC
UPLOAD · Letter from the SECApr 7, 2026Other filingsSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2026Insider tradeSEC
6-K · Report of a foreign issuerMar 19, 2026Current reportSEC
Update on Phase I Study of IMP761 for Autoimmune DiseasesMar 18, 2026Other filingsASX
6-K · Report of a foreign issuerMar 16, 2026Current reportSEC
Reinstatement to QuotationMar 12, 2026Trading halt or suspensionASX
TACTI-004 to be discontinued following futility analysisMar 12, 2026Operations updateASX
Suspension from QuotationMar 10, 2026Trading halt or suspensionASX
Trading HaltMar 6, 2026Trading halt or suspensionASX
6-K · Report of a foreign issuerFeb 25, 2026Current reportSEC
Half Yearly Report and AccountsFeb 24, 2026Interim reportASX
6-K · Report of a foreign issuerFeb 9, 2026Current reportSEC
Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLCFeb 5, 2026Operations updateASX
6-K · Report of a foreign issuerJan 29, 2026Current reportSEC
Immutep Quarterly Activities Report and Appendix 4CJan 29, 2026Quarterly reportASX
6-K · Report of a foreign issuerDec 22, 2025Current reportSEC
Positive Update on IMP761 Phase 1Dec 21, 2025Operations updateASX
6-K · Report of a foreign issuerDec 16, 2025Current reportSEC
TACTI-004 phase III trial enrolment continues at robust paceDec 15, 2025Operations updateASX
6-K · Report of a foreign issuerDec 9, 2025Current reportSEC
Immutep enters into Strategic Collaboration with Dr. Reddy'sDec 8, 2025Acquisition or disposalASX
6-K · Report of a foreign issuerDec 2, 2025Current reportSEC
New data presentation from AIPAC-003 Phase II for SABCSDec 1, 2025Operations updateASX
6-K · Report of a foreign issuerNov 13, 2025Current reportSEC
EFTISARC-NEO Phase II results presented at CTOS 2025Nov 12, 2025ResultsASX
6-K · Report of a foreign issuerNov 3, 2025Current reportSEC
Immutep Receives A$4.6 million French R&D Tax IncentiveNov 2, 2025FinancingASX
6-K · Report of a foreign issuerOct 30, 2025Current reportSEC
20-F · Annual reportOct 24, 2025Annual reportSEC
6-K · Report of a foreign issuerOct 21, 2025Current reportSEC
6-K · Report of a foreign issuerOct 20, 2025Current reportSEC
Primary Endpoint Met in STS Trial - presented at ESMO 2025Oct 19, 2025ResultsASX
Improved ORR in First Line NSCLC - presented at ESMO 2025Oct 19, 2025Other filingsASX
6-K · Report of a foreign issuerOct 14, 2025Current reportSEC
Successful Completion of FDA Project Optimus RequirementsOct 12, 2025Operations updateASX
6-K · Report of a foreign issuerOct 9, 2025Current reportSEC
TACTI-004 (KEYNOTE-F91) Phase 3 update in First Line NSCLCOct 8, 2025Other filingsASX
6-K · Report of a foreign issuerSep 22, 2025Current reportSEC
New investigator-initiated Phase II trial for EftiSep 21, 2025Operations updateASX
6-K · Report of a foreign issuerSep 2, 2025Current reportSEC
Appendix 4E & 2025 Full Year Statutory AccountsAug 28, 2025Annual reportASX
6-K · Report of a foreign issuerAug 6, 2025Current reportSEC
FDA feedback received for head & neck cancer in CPS below 1Aug 4, 2025Other filingsASX
6-K · Report of a foreign issuerJul 30, 2025Current reportSEC
6-K · Report of a foreign issuerJun 23, 2025Current reportSEC
6-K · Report of a foreign issuerMay 27, 2025Current reportSEC
Primary Endpoint Met in Phase II Soft Tissue Sarcoma TrialMay 25, 2025Operations updateASX
6-K · Report of a foreign issuerMay 15, 2025Current reportSEC
High Response Rates achieved in Lung Cancer in INSIGHT-003May 14, 2025Operations updateASX
6-K · Report of a foreign issuerMay 5, 2025Current reportSEC
Excellent Overall Survival in Head & Neck Cancer PatientsMay 4, 2025ResultsASX
6-K · Report of a foreign issuerApr 29, 2025Current reportSEC
6-K · Report of a foreign issuerMar 25, 2025Current reportSEC
First patient dosed in phase 3 TACTI-004 lung cancer trialMar 24, 2025Operations updateASX
6-K · Report of a foreign issuerFeb 27, 2025Current reportSEC
6-K · Report of a foreign issuerFeb 3, 2025Current reportSEC
6-K · Report of a foreign issuerDec 17, 2024Current reportSEC
Immutep announces initial safety data from IMP761 phase 1Dec 16, 2024Operations updateASX
6-K · Report of a foreign issuerDec 12, 2024Current reportSEC
Immutep Reports Promising New Data in Head and Neck CancerDec 11, 2024ResultsASX
6-K · Report of a foreign issuerDec 10, 2024Current reportSEC
Initiation of TACTI-004 phase 3 trial in 1st line NSCLCDec 9, 2024Operations updateASX
6-K · Report of a foreign issuerNov 15, 2024Current reportSEC
6-K · Report of a foreign issuerNov 14, 2024Current reportSEC
Excellent Survival Data from INSIGHT-003 Trial in NSCLCNov 13, 2024ResultsASX
Positive Data from Phase II Trial in Soft Tissue SarcomaNov 13, 2024Other filingsASX
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerOct 29, 2024Current reportSEC
20-F · Annual reportOct 22, 2024Annual reportSEC
6-K · Report of a foreign issuerOct 3, 2024Current reportSEC
Enrolment for Ph II AIPAC-003 Breast Cancer Trial CompletedOct 3, 2024Other filingsASX
6-K · Report of a foreign issuerSep 24, 2024Current reportSEC
Immutep receives A$3.6 million French R&D Tax IncentiveSep 23, 2024Other filingsASX
6-K · Report of a foreign issuerSep 16, 2024Current reportSEC
New Positive Efficacy Data for Efti in Head and Neck CancerSep 15, 2024ResultsASX
6-K · Report of a foreign issuerSep 9, 2024Current reportSEC
S&P DJI Announces September 2024 Quarterly RebalanceSep 6, 2024Other filingsASX
6-K · Report of a foreign issuerSep 3, 2024Current reportSEC
Appendix 4E & 2024 Full Year Statutory AccountsAug 30, 2024Annual reportASX
6-K · Report of a foreign issuerAug 20, 2024Current reportSEC
TACTI-003 data selected for oral presentation at ESMO 2024Aug 20, 2024Other filingsASX
6-K · Report of a foreign issuerAug 14, 2024Current reportSEC
First Participant Dosed in Phase I Study of IMP761Aug 13, 2024Other filingsASX
6-K · Report of a foreign issuerJul 31, 2024Current reportSEC
6-K · Report of a foreign issuerJul 23, 2024Current reportSEC
Successful Meeting with FDA on Phase III Design in NSCLCJul 21, 2024Operations updateASX
6-K · Report of a foreign issuerJul 17, 2024Current reportSEC
Regulatory Clearance received for Phase 1 trial of IMP761Jul 16, 2024Other filingsASX
6-K · Report of a foreign issuerJul 12, 2024Current reportSEC
Webcast to discuss data presented at ESMO Plenary SessionJul 11, 2024Operations updateASX
Positive results in TACTI-003 for 1L HNSCC cohort B patientsJul 11, 2024ResultsASX
6-K · Report of a foreign issuerJul 3, 2024Current reportSEC
6-K · Report of a foreign issuerJun 28, 2024Current reportSEC
Webcast slides for new Efti clinical data in 1st line HNSCCJun 26, 2024Other filingsASX
Positive topline results from ph2b in head & neck cancerJun 26, 2024Other filingsASX
6-K · Report of a foreign issuerJun 25, 2024Current reportSEC
6-K · Report of a foreign issuerJun 24, 2024Current reportSEC
Immutep completes underwritten retail entitlement offerJun 24, 2024FinancingASX
6-K · Report of a foreign issuerJun 5, 2024Current reportSEC
Immutep completes institutional pro-rata offer & placementJun 4, 2024FinancingASX
6-K · Report of a foreign issuerJun 4, 2024Current reportSEC
Immutep announces Ph 3 clinical trial collaboration with MSDJun 3, 2024Operations updateASX
Immutep Capital Raising PresentationJun 2, 2024FinancingASX
A$100 million fully underwritten equity raisingJun 2, 2024Other filingsASX
6-K · Report of a foreign issuerMay 15, 2024Current reportSEC
AIPAC-003 safety lead-in data presented at ESMO Breast 2024May 15, 2024Operations updateASX
6-K · Report of a foreign issuerMay 2, 2024Current reportSEC
Positive initial data in phase 2 Soft Tissue Sarcoma trialMay 1, 2024Operations updateASX
6-K · Report of a foreign issuerApr 30, 2024Current reportSEC
6-K · Report of a foreign issuerApr 24, 2024Current reportSEC
Positive preliminary topline results from TACTI-003 Cohort BApr 23, 2024Other filingsASX
6-K · Report of a foreign issuerApr 18, 2024Current reportSEC
CHDR to conduct first-in-human phase 1 trial of IMP761Apr 17, 2024Other filingsASX
6-K · Report of a foreign issuerMar 5, 2024Current reportSEC
First Clinical Data announced from 90mg Dosing of EftiMar 5, 2024Operations updateASX
6-K · Report of a foreign issuerFeb 29, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerJan 30, 2024Current reportSEC
6-K · Report of a foreign issuerDec 21, 2023Current reportSEC
PEI provides constructive feedback for ph3 lung cancer trialDec 20, 2023Other filingsASX
6-K · Report of a foreign issuerDec 7, 2023Current reportSEC
Immutep receives A$2.6 million French R&D Tax IncentiveDec 6, 2023FinancingASX
6-K · Report of a foreign issuerNov 9, 2023Current reportSEC
Immutep Completes Enrolment for TACTI-003 Phase IIb TrialNov 8, 2023Operations updateASX
6-K · Report of a foreign issuerNov 6, 2023Current reportSEC
Lead-in phase completed for ph2/3 trial in Breast CancerNov 5, 2023Operations updateASX
6-K · Report of a foreign issuerNov 3, 2023Current reportSEC
New Biomarker Data from TACTI-002 trial in 1st line NSCLCNov 2, 2023Operations updateASX
6-K · Report of a foreign issuerOct 31, 2023Current reportSEC
6-K · Report of a foreign issuerOct 25, 2023Current reportSEC
6-K · Report of a foreign issuerOct 24, 2023Current reportSEC
20-F · Annual reportOct 24, 2023Annual reportSEC
6-K · Report of a foreign issuerOct 24, 2023Current reportSEC
Immutep reports promising data from INSIGHT-003 trialOct 23, 2023Operations updateASX
Webcast slides for new Efti clinical data in 1st line NSCLCOct 22, 2023Operations updateASX
Excellent Overall Survival in Non-Small Cell Lung CancerOct 22, 2023Other filingsASX
6-K · Report of a foreign issuerOct 16, 2023Current reportSEC
Immutep announces publication of ESMO 2023 abstractsOct 15, 2023Other filingsASX
6-K · Report of a foreign issuerSep 21, 2023Current reportSEC
Commercial Scale Manufacturing of Efti for Clinical TrialsSep 20, 2023Other filingsASX
Appendix 4E & 2023 Full Year Statutory AccountsAug 29, 2023Annual reportASX
6-K · Report of a foreign issuerAug 1, 2023Current reportSEC
Immutep receives positive scientific advice from EMAAug 1, 2023Other filingsASX
6-K · Report of a foreign issuerJul 31, 2023Current reportSEC
6-K · Report of a foreign issuerJul 28, 2023Current reportSEC
1st Patient Dosed in Phase 2 Soft Tissue Sarcoma TrialJul 27, 2023Other filingsASX

This page holds 200 of 1,037 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Immutep Ltd’s releases

Common shares
1,473,721,306
Fully diluted
1,473,721,306

Fully diluted

LineShares
Common shares1,473,721,306

Share count over time

CountShares
Nov 22, 20261,473,721,306

Open Cap table

Shareholders

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Pete Meyers
Other companies: Eagle Pharmaceuticals, Inc. (Chief Financial Officer · May 15, 2017 – Jan 23, 2020 · Past); Tetralogic Pharmaceuticals Corp (CFO & Treasurer · Dec 11, 2013 – Mar 27, 2015 · Past)
Director · Since at least Mar 18, 2026
Chris BastaVP, Investor Relations and Corporate Communications · Since at least Feb 6, 2026
Christian MuellerChief Development Officer · Since at least Oct 13, 2025
David FangFinance Director & Assistant Company Secretary · Since at least Nov 4, 2026
Deanne MillerChief Operating Officer, General Counsel & Company Secretary · Since at least Mar 18, 2026
Elisabeth Amanda BoyceDirector · Since at least Mar 18, 2026
Frédéric TriebelChief Scientific Officer & Executive Director · Since at least Mar 18, 2026
James FlinnIntellectual Property Director & Legal Counsel · Since at least Nov 4, 2026
Lis BoyceNon-Executive Director · Since at least Nov 5, 2026
Marc VoigtChief Executive Officer & Executive Director · Since at least Mar 18, 2026
All 12 people
PersonSeat
Russell HowardNon-Executive Chairman · Since at least Mar 18, 2026
Stephan WinckelsChief Medical Officer · Since at least Oct 29, 2025

Open People

Log in to ask 6ix AI your own questions about Immutep Ltd.